Computational Modeling of RdRp Inhibitors for the Development of Drugs against Novel Coronavirus (nCoV)
Author:
Kumar Vinay,Roy Kunal
Reference96 articles.
1. McKee DL, Sternberg A, Stange U, Laufer S, Naujokat C (2020) Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol Res 157:104859. https://doi.org/10.1016/j.phrs.2020.104859 2. Pyrc K, Jebbink MF, Vermeulen OW, Berkhout RJ, Wolthers KC, Wertheim van PD, Kaandorp J, Spaargaren J, Berkhout B (2004) Identification of a new human coronavirus. Nat Med 10(4):368–373. https://doi.org/10.1038/nm1024 3. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, Sagnelli C, Bianchi M, Bernardini S, Ciccozzi M (2019) COVID-19 outbreak: an overview. Chemotherapy 64(5–6):215–223. https://doi.org/10.1159/000507423 4. Liu C, Qiongqiong Z, Li Y, Linda V, Garner S, Linda JC, Jeffrey S (2020) Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases. ACS Cent Sci 6:315–331. https://doi.org/10.1021/acscentsci.0c00272 5. Cheng H, Wang Y, Wang GQ (2020) Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol 92(7):726–730. https://doi.org/10.1002/jmv.25785
|
|